Login

Journal Image
Recent Patents on Biotechnology
ISSN (Print): 1872-2083
ISSN (Online): 2212-4012
VOLUME: 6
ISSUE: 1
DOI: 10.2174/187220812799789190









Monoclonal Antibodies as Cancer Therapeutics

img
Author(s): Jihene Elloumi, Karim Jellali, Ikram Jemel and Sami Aifa
Pages 45-56 (12)
Abstract:
Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Keywords:
Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Affiliation:
Centre of Biotechnology of Sfax, PoBox 1177, 3018, Sfax University, Sfax, Tunisia